Daily close, T-120 (1/24/25) through T+5. Run-up high $15.95 on 2/21/25, low $6.34 on 5/14/25 (T-120 to T-1). FDA decision 7/11/25. Historical price action, not a forecast.
Positioning before the decision
On Jun 27, 2025, 14 days before the decision date, at-the-money options priced a move of ±24.2% through Jul 18, 2025 (the first listed expiry after the decision; ATM implied volatility 128%). The stock closed -33.0% at the first close across the decision and -37.2% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Not in this review cycle. On July 11, 2025 the FDA issued a Complete Response Letter, declining to approve the application for source-verified in its current form. A CRL is not final; the primary source is linked on this page.
How did CAPR stock react to the FDA decision?
On the decision day CAPR moved -33.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.